News >

Weiss Weighs In on Challenges in NSCLC

Danielle Bucco
Published: Thursday, Mar 29, 2018

Jared Weiss, MD

Jared Weiss, MD
Although significant progress has been made to the treatment landscape for patients with non–small cell lung cancer (NSCLC), challenges remain with varying novel treatment strategies, explains Jared Weiss, MD.

State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Weiss, an assistant professor, Thoracic Oncology Program, University of North Carolina (UNC)-Chapel Hill, UNC Lineberger Comprehensive Cancer Center, and chair of the meeting, offered his insight on challenges in the field of NSCLC.

OncLive: Can you discuss challenges surrounding TKIs for the frontline treatment of patients with NSCLC?

Weiss: One question I am frequently asked, as newer TKIs are introduced into clinical practice, is, “What will I do next if I use more potent agents first?” In the case of EGFR-mutated NSCLC, we are talking about potentially using osimertinib (Tagrisso) in the frontline setting instead of gefitinib (Iressa), erlotinib (Tarceva), or afatinib (Gilotrif). In the case of ALK-rearranged NSCLC, we are talking about using alectinib (Alecensa) in the frontline setting instead of crizotinib (Xalkori). 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x